Briacell Therapeutics Corp (NASDAQ:BCTX) — Market Cap & Net Worth
Market Cap & Net Worth: Briacell Therapeutics Corp (BCTX)
Briacell Therapeutics Corp (NASDAQ:BCTX) has a market capitalization of $29.93 Million ($29.93 Million) as of August 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23719 globally and #5080 in its home market, demonstrating a -7.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Briacell Therapeutics Corp's stock price $3.44 by its total outstanding shares 8699787 (8.70 Million). See reinvestment intensity of Briacell Therapeutics Corp to understand how much of operating cash flow is reinvested back into capital assets.
Briacell Therapeutics Corp Market Cap History: 2015 to 2026
Briacell Therapeutics Corp's market capitalization history from 2015 to 2026. Data shows change from $475.37 Million to $29.93 Million (-23.62% CAGR).
Index Memberships
Briacell Therapeutics Corp is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2240 of 3165 |
Weight: Briacell Therapeutics Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Briacell Therapeutics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Briacell Therapeutics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BCTX by Market Capitalization
Companies near Briacell Therapeutics Corp in the global market cap rankings as of August 2, 2026.
Key companies related to Briacell Therapeutics Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Briacell Therapeutics Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Briacell Therapeutics Corp's market cap moved from $475.37 Million to $ 29.93 Million, with a yearly change of -23.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $29.93 Million | -51.62% |
| 2025 | $61.86 Million | +1158.41% |
| 2024 | $4.92 Million | -90.34% |
| 2023 | $50.89 Million | +35.16% |
| 2022 | $37.65 Million | -47.22% |
| 2021 | $71.34 Million | +98.56% |
| 2020 | $35.93 Million | -57.62% |
| 2019 | $84.79 Million | -37.52% |
| 2018 | $135.71 Million | -47.66% |
| 2017 | $259.27 Million | -33.13% |
| 2016 | $387.74 Million | -18.43% |
| 2015 | $475.37 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Briacell Therapeutics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.93 Million USD |
| MoneyControl | $29.93 Million USD |
| MarketWatch | $29.93 Million USD |
| marketcap.company | $29.93 Million USD |
| Reuters | $29.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more